Gilead Sciences Settles Counterfeit HIV Drug Legal Case

Gilead Sciences has agreed to settle for an undisclosed amount with several defendants over an alleged scheme involving its human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) drugs.

The lawsuit involved alleged fraud in using the company’s PrEP drug access program to pocket reimbursement payments, which the company said had cost it more than $68 million.

Under the terms of the settlement, the defendants, including members of the Vasselov family who operated a United Pharmacy store in Florida that has since shut down, will be barred from using Gilead’s access program.

The company first filed a complaint in Florida over the alleged scheme in November 2020.